The concern of generic competition has consistently loomed over copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of similar drug portfolios. While initial periods saw significant returns, the intellectual property expiration has allowed the door for cheaper substitutes, potentially lowering earnings and creating a r